|
4 Products |
| 4 Products |
|
89 Diseases |  |
187 News |  |
| «1234» |
- ||||| Arenegyr (NGR-hTNF) / Molmed, Rituxan (rituximab) / Roche, Biogen
Interesting paper on relapsed CNS #lymphoma treated with R-CHOP after increased vessels permeability TNF alpha coupled with NGR (NGR-hTNF), a peptide targeting CD13+ vessels by Andre Ferreri et al in @BloodJournal https://t.co/5kjo6sm57W (Twitter) - Jul 21, 2019
- | ubenimex (DFP-14323) - Delta / Fly Pharma
Trial completion: Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA) (clinicaltrials.gov) - Jul 16, 2019
P2, N=46, Completed, Sponsor: Eiger BioPharmaceuticals
Active, not recruiting --> Completed
- | Arenegyr (NGR-hTNF) / Molmed
Clinical, P3 data, Journal, Combination therapy: NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. (Pubmed Central) - Apr 11, 2019
P3
The study did not meet its primary endpoint. The hypothesis-generating findings from the subgroup analyses deserve a confirmatory randomised trial because patients who rapidly progress after first-line treatment have a poor prognosis.
- ||| Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Enrollment change, Metastases: Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM (clinicaltrials.gov) - Jan 16, 2019
P2, N=137, Completed, Sponsor: MolMed S.p.A.
The hypothesis-generating findings from the subgroup analyses deserve a confirmatory randomised trial because patients who rapidly progress after first-line treatment have a poor prognosis. Active, not recruiting --> Completed | N=100 --> 137
- || Arenegyr (NGR-hTNF) / AGC Biologics
New P2 trial, Combination therapy: NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018) (clinicaltrials.gov) - Jan 15, 2019
P2, N=14, Completed, Sponsor: MolMed S.p.A.
- ||| STR-324 / ArchiMed
Trial completion: First-In-Human PainCart Study for STR-324 (clinicaltrials.gov) - Dec 12, 2018
P1, N=78, Completed, Sponsor: Stragen France
Active, not recruiting --> Completed | N=100 --> 137 Recruiting --> Completed
- | ubenimex (DFP-14323) - Delta / Fly Pharma
Trial completion date: Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA) (clinicaltrials.gov) - Nov 14, 2018
P2, N=46, Active, not recruiting, Sponsor: Eiger BioPharmaceuticals
Recruiting --> Completed Trial completion date: Nov 2018 --> Feb 2019
- | Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Combination therapy, Metastases: Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer (clinicaltrials.gov) - Sep 27, 2018
P2, N=37, Completed, Sponsor: MolMed S.p.A.
Trial completion date: Nov 2018 --> Feb 2019 Active, not recruiting --> Completed
- | Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Trial completion date, Trial primary completion date, Combination therapy: Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer (clinicaltrials.gov) - Sep 27, 2018
P2, N=119, Completed, Sponsor: MolMed S.p.A.
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Jun 2017 --> Dec 2016 | Trial primary completion date: Jun 2016 --> Dec 2016
- | Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases: NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Sep 27, 2018
P2, N=121, Completed, Sponsor: MolMed S.p.A.
Active, not recruiting --> Completed | Trial completion date: Jun 2017 --> Dec 2016 | Trial primary completion date: Jun 2016 --> Dec 2016 Active, not recruiting --> Completed | Trial completion date: Jun 2016 --> Mar 2017 | Trial primary completion date: Jun 2016 --> Mar 2017
- | ubenimex (DFP-14323) - Delta / Fly Pharma
Trial completion date, Trial termination, Trial primary completion date: LIBERTY2: Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) (clinicaltrials.gov) - Sep 17, 2018
P2, N=51, Terminated, Sponsor: Eiger BioPharmaceuticals
Active, not recruiting --> Completed | Trial completion date: Jun 2016 --> Mar 2017 | Trial primary completion date: Jun 2016 --> Mar 2017 Trial completion date: Nov 2018 --> Aug 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2018 --> Mar 2018; Following the failure to demonstrate efficacy in EIG-UBX-001, the sponsor decided to terminate Study EIG-UBX-002.
- | Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Trial completion date, Trial primary completion date, Metastases: Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour (clinicaltrials.gov) - Aug 29, 2018
P1, N=48, Completed, Sponsor: MolMed S.p.A.
Trial completion date: Nov 2018 --> Aug 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2018 --> Mar 2018; Following the failure to demonstrate efficacy in EIG-UBX-001, the sponsor decided to terminate Study EIG-UBX-002. Active, not recruiting --> Completed | Trial completion date: Jun 2016 --> Feb 2017 | Trial primary completion date: Jun 2016 --> Feb 2017
- | Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Trial completion date, Combination therapy, Metastases: Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas. (clinicaltrials.gov) - Aug 29, 2018
P2, N=69, Completed, Sponsor: MolMed S.p.A.
Active, not recruiting --> Completed | Trial completion date: Jun 2016 --> Feb 2017 | Trial primary completion date: Jun 2016 --> Feb 2017 Active, not recruiting --> Completed | Trial completion date: Jun 2017 --> May 2016
- | Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases: NGR007: Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma (clinicaltrials.gov) - Aug 29, 2018
P2, N=28, Completed, Sponsor: MolMed S.p.A.
Active, not recruiting --> Completed | Trial completion date: Jun 2017 --> May 2016 Active, not recruiting --> Completed | Trial completion date: Jun 2016 --> Nov 2015 | Trial primary completion date: Jun 2016 --> Nov 2015
- | Arenegyr (NGR-hTNF) / AGC Biologics
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM (clinicaltrials.gov) - Aug 29, 2018
P2, N=100, Active, not recruiting, Sponsor: MolMed S.p.A.
Active, not recruiting --> Completed | Trial completion date: Jun 2016 --> Nov 2015 | Trial primary completion date: Jun 2016 --> Nov 2015 Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2016 --> Dec 2018
- |||| ubenimex (DFP-14323) - Delta / Fly Pharma
Trial completion: LIBERTY: A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) (clinicaltrials.gov) - Mar 2, 2018
P2, N=61, Completed, Sponsor: Eiger BioPharmaceuticals
Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2016 --> Dec 2018 Active, not recruiting --> Completed
- | STR-324 / ArchiMed
Enrollment open: First-In-Human PainCart Study for STR-324 (clinicaltrials.gov) - Feb 26, 2018
P1, N=78, Recruiting, Sponsor: Stragen France
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | STR-324 / ArchiMed
New P1 trial: First-In-Human PainCart Study for STR-324 (clinicaltrials.gov) - Feb 11, 2018
P1, N=78, Not yet recruiting, Sponsor: Stragen France
- ubenimex (DFP-14323) - Delta / Fly Pharma
Trial primary completion date: LIBERTY2: Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) (clinicaltrials.gov) - Feb 5, 2018
P2, N=45, Active, not recruiting, Sponsor: Eiger BioPharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2017 --> Jul 2018
- ubenimex (DFP-14323) - Delta / Fly Pharma
Trial primary completion date: Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA) (clinicaltrials.gov) - Feb 5, 2018
P2, N=46, Active, not recruiting, Sponsor: Eiger BioPharmaceuticals
Trial primary completion date: Nov 2017 --> Jul 2018 Trial primary completion date: Nov 2017 --> Sep 2018
- ||||||| Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Trial primary completion date, Metastases: NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed (clinicaltrials.gov) - Dec 22, 2017
P3, N=400, Completed, Sponsor: MolMed S.p.A.
Trial primary completion date: Nov 2017 --> Sep 2018 Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Dec 2017
- | ubenimex (DFP-14323) - Delta / Fly Pharma
Enrollment closed: Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA) (clinicaltrials.gov) - Nov 30, 2017
P2, N=46, Active, not recruiting, Sponsor: Eiger BioPharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Active, not recruiting
- | ubenimex (DFP-14323) - Delta / Fly Pharma
Enrollment closed: LIBERTY2: Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) (clinicaltrials.gov) - Aug 23, 2017
P2, N=45, Active, not recruiting, Sponsor: Eiger BioPharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| ubenimex (DFP-14323) - Delta / Fly Pharma
Enrollment closed, Enrollment change: LIBERTY: A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) (clinicaltrials.gov) - Jul 6, 2017
P2, N=61, Active, not recruiting, Sponsor: Eiger BioPharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=45 --> 61
- | ubenimex (DFP-14323) - Delta / Fly Pharma
Enrollment open: LIBERTY2: Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) (clinicaltrials.gov) - Mar 5, 2017
P2, N=45, Recruiting, Sponsor: Eiger BioPharmaceuticals
Recruiting --> Active, not recruiting | N=45 --> 61 Not yet recruiting --> Recruiting
- | ubenimex (DFP-14323) - Delta / Fly Pharma
Enrollment open: Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA) (clinicaltrials.gov) - Jun 23, 2016
P2, N=45, Recruiting, Sponsor: Eiger BioPharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | ubenimex (DFP-14323) - Delta / Fly Pharma
New P2 trial: LIBERTY2: Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) (clinicaltrials.gov) - Apr 13, 2016
P2, N=45, Not yet recruiting, Sponsor: Eiger BioPharmaceuticals
- | ubenimex (DFP-14323) - Delta / Fly Pharma
Enrollment open: LIBERTY: A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) (clinicaltrials.gov) - Apr 8, 2016
P2, N=45, Recruiting, Sponsor: Eiger BioPharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | ubenimex (DFP-14323) - Delta / Fly Pharma
New P2 trial: Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA) (clinicaltrials.gov) - Mar 7, 2016
P2, N=45, Not yet recruiting, Sponsor: Eiger BioPharmaceuticals
- | ubenimex (DFP-14323) - Delta / Fly Pharma
New P2 trial: LIBERTY: A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) (clinicaltrials.gov) - Jan 27, 2016
P2, N=45, Not yet recruiting, Sponsor: Eiger BioPharmaceuticals
- || Arenegyr (NGR-hTNF) / AGC Biologics
Trial primary completion date, Metastases: Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM (clinicaltrials.gov) - Oct 22, 2015
P2, N=100, Recruiting, Sponsor: MolMed S.p.A.
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2016 --> Dec 2016
- |||| Arenegyr (NGR-hTNF) / AGC Biologics
Trial primary completion date, Metastases: NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed (clinicaltrials.gov) - Oct 22, 2015
P3, N=390, Active, not recruiting, Sponsor: MolMed S.p.A.
Trial primary completion date: Jun 2016 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- || Arenegyr (NGR-hTNF) / AGC Biologics
Trial primary completion date, Combination therapy, Metastases: NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Oct 22, 2015
P2, N=102, Active, not recruiting, Sponsor: MolMed S.p.A.
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Jun 2016
- Arenegyr (NGR-hTNF) / AGC Biologics
Trial primary completion date, Metastases: Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour (clinicaltrials.gov) - Oct 22, 2015
P1, N=48, Active, not recruiting, Sponsor: MolMed S.p.A.
Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Dec 2015 --> Jun 2016
- Arenegyr (NGR-hTNF) / AGC Biologics
Trial primary completion date, Combination therapy, Metastases: Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer (clinicaltrials.gov) - Oct 22, 2015
P2, N=37, Active, not recruiting, Sponsor: MolMed S.p.A.
Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Dec 2015 --> Jun 2016
- Arenegyr (NGR-hTNF) / AGC Biologics
Trial primary completion date, Combination therapy, Metastases: NGR007: Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma (clinicaltrials.gov) - Oct 22, 2015
P2, N=28, Active, not recruiting, Sponsor: MolMed S.p.A.
Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Dec 2015 --> Jun 2016
- || Arenegyr (NGR-hTNF) / AGC Biologics
Trial primary completion date, Metastases: Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM (clinicaltrials.gov) - Apr 14, 2015
P2, N=100, Recruiting, Sponsor: MolMed S.p.A.
Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Jun 2013 --> Jun 2016
- |||| Arenegyr (NGR-hTNF) / AGC Biologics
Trial primary completion date, Metastases: NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed (clinicaltrials.gov) - Apr 14, 2015
P3, N=390, Active, not recruiting, Sponsor: MolMed S.p.A.
Trial primary completion date: Jun 2013 --> Jun 2016 Trial primary completion date: Nov 2013 --> Dec 2015
- || Arenegyr (NGR-hTNF) / AGC Biologics
Trial primary completion date, Combination therapy, Metastases: NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 14, 2015
P2, N=102, Active, not recruiting, Sponsor: MolMed S.p.A.
Trial primary completion date: Nov 2013 --> Dec 2015 Trial primary completion date: Sep 2013 --> Dec 2015
- Arenegyr (NGR-hTNF) / AGC Biologics
Trial primary completion date, Metastases: Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour (clinicaltrials.gov) - Apr 14, 2015
P1, N=48, Active, not recruiting, Sponsor: MolMed S.p.A.
Trial primary completion date: Sep 2013 --> Dec 2015 Trial primary completion date: Jun 2013 --> Dec 2015
- Arenegyr (NGR-hTNF) / AGC Biologics
Trial primary completion date, Combination therapy, Metastases: Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer (clinicaltrials.gov) - Apr 14, 2015
P2, N=37, Active, not recruiting, Sponsor: MolMed S.p.A.
Trial primary completion date: Jun 2013 --> Dec 2015 Trial primary completion date: Feb 2013 --> Dec 2015
- Arenegyr (NGR-hTNF) / AGC Biologics
Trial primary completion date, Combination therapy, Metastases: NGR007: Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma (clinicaltrials.gov) - Apr 14, 2015
P2, N=28, Active, not recruiting, Sponsor: MolMed S.p.A.
Trial primary completion date: Feb 2013 --> Dec 2015 Trial primary completion date: Jan 2013 --> Dec 2015
- ||| Arenegyr (NGR-hTNF) / AGC Biologics
Enrollment closed, Trial primary completion date, Combination therapy: Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer (clinicaltrials.gov) - Apr 6, 2015
P2, N=124, Active, not recruiting, Sponsor: MolMed S.p.A.
Trial primary completion date: Jan 2013 --> Dec 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Jun 2016
- ||| Arenegyr (NGR-hTNF) / AGC Biologics
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas. (clinicaltrials.gov) - Apr 6, 2015
P2, N=96, Active, not recruiting, Sponsor: MolMed S.p.A.
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Jun 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Jun 2016
- simvastatin / Generic mfg.
Trial completion, Enrollment change: The Effects of Simvastatin on Th17 Cytokines and Th17 Polarizing Cytokine in COPD Patients (clinicaltrials.gov) - Sep 19, 2014
P3, N=24, Completed, Sponsor: Mahidol University
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Jun 2016 Recruiting --> Completed | N=30 --> 24
- | Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Combination therapy, Metastases: NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - May 28, 2014
P2, N=24, Completed, Sponsor: MolMed S.p.A.
Recruiting --> Completed | N=30 --> 24 Active, not recruiting --> Completed
- |||| Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Metastases: Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma (clinicaltrials.gov) - May 28, 2014
P2, N=57, Completed, Sponsor: MolMed S.p.A.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Metastases: Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - May 28, 2014
P2, N=40, Completed, Sponsor: MolMed S.p.A.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion: Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC) (clinicaltrials.gov) - May 28, 2014
P2, N=46, Completed, Sponsor: MolMed S.p.A.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Combination therapy, Metastases: Study of NGR-hTNF in Combination With Cisplatin in Solid Tumor (clinicaltrials.gov) - May 28, 2014
P1, N=22, Completed, Sponsor: MolMed S.p.A.
Active, not recruiting --> Completed Active, not recruiting --> Completed